To further explore the benefits of mouthwash against the Covid-19 virus, Unilever has joined forces with the Liverpool School of Tropical Medicine to conduct additional studies. This includes ex vivo laboratory tests of CPC-based mouthwash on human saliva, which will be important in better understanding the mechanism by which mouthwash could help in reducing the transmission of the virus.

Internationally recognised as being at the forefront of scientific research into infectious diseases, the Liverpool School of Tropical Medicine is playing a leading role in the UK in assessing the effectiveness of treatments and preventative measures relating to Covid-19.

The joint research programme with Unilever is backed by the UK government's Strength in Places Fund which looks to deliver innovative solutions to tackling human infections. As one of the first studies to benefit from the fund, Unilever and the Liverpool School of Tropical Medicine will aim to develop new products that can directly reduce the burden of infectious diseases in the UK and around the world.

Senior Lecturer at the Liverpool School of Tropical Medicine Dr Grant Hughes says the collaboration highlights the value of academia and industry working together in the infection-related R&D ecosystem: 'This academic-business partnership is a key collaboration in the fight against Covid-19 and offers a real opportunity for providing a low-cost, easy and readily available preventative measure to support the public health agenda, including in the poorest of countries.'

Attachments

  • Original document
  • Permalink

Disclaimer

Unilever plc published this content on 20 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 January 2021 14:17:02 UTC